ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1220

Effect of Anti-Diabetic Medications on Fracture Risk in Type II Diabetes Mellitus

Youmna Lahoud1, Christine Peloquin1, Yuqing Zhang2 and Devyani Misra3, 1Boston University School of Medicine, Boston, MA, 2School Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 3Medicine, Section of, Boston University School of Medicine, Boston, MA

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: diabetes and fracture risk, Hip

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 6, 2017

Session Title: Osteoporosis and Metabolic Bone Disease – Clinical Aspects and Pathogenesis Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Risk of osteoporotic fracture in type II Diabetes Mellitus is conflicting and possibly related to the anti-diabetic medication used. There is evidence to suggest protective effect of some medications (e.g. metformin and sulfonylureas) while others have been associated with increased risk for fractures (e.g. thiazolidinedione and DPP4-inhibitors).  Thus, we examined the association of oral anti-diabetic medications with hip fractures risk in community-dwelling older adults with type 2 Diabetes Mellitus.

Methods: We conducted a nested case-control study in men and women ≥ 40 years old with incident (new-onset) type II Diabetes Mellitus, from The Health Improvement Network (THIN), an electronic medical records database from the United Kingdom. For each incident (new-onset) hip fracture case, we selected up to 4 controls matched by age and sex. We categorized the anti-diabetic medications into the following categories: 1) Current use (last prescription within 1 year) of Metformin alone; 2) Current use of Sulfonylureas alone; 3) Current use of Thiazolidinediones or DPP4 inhibitors alone; 4) Current use of combinations or others; 5) Current use of any drug with recent switch in category; 6) Remote use of any medications (last prescription >1 year ago) as the reference category.  In a multivariable conditional logistic model, we adjusted for alcoholism/heavy drinking, BMI, fall/high risk of falls, smoking and medications (ace inhibitors, anti-osteoporosis medications, anti-seizure drugs, beta-blockers, diuretics, estrogen, glucocorticoids).

Results: Among 2673 subjects (mean age 72y; 70% women; 447 incident hip fracture cases and 2226 controls), the hip fractures cases had lower BMI and were more likely to have alcoholism and falls. As shown in Table, compared to remote use of any oral anti-diabetic medications, the odds for hip fracture was reduced by 36% with current metformin use (OR 0.64, 95% CI 0.49- 0.84), no different with current use of sulfonylureas (OR 1.02, 95%CI 0.76-1.38) and slightly increased, although not statistically significant, with current Thiazolidinedione or DPP-4 inhibitors (OR 1.29, 95%CI 0.69-2.43) use.

Conclusion:   We found protective effect of metformin use, no effect of sulfonylureas and possibly adverse effect of Thiazolidinedione and DPP-4 inhibitors on hip fracture risk in this large cohort of older diabetic patients. Clinicians caring for older diabetic patients need to consider fracture risk while selecting anti-diabetic medications.

Table: Association of Anti-diabetic Medications with Odds of Hip Fracture

Oral anti-diabetic medications use

Hip Fracture Cases

Controls

Crude OR

Adjusted OR

Current Metformin

449

2246

0.57 (0.45, 0.74)

0.65 (0.50, 0.84)

Current Sulfonylureas

209

602

1.05 (0.79, 1.39)

1.05 (0.78, 1.40)

Current Thiazolidinedione or DPP-4 inhibitors

16

47

0.99 (0.54, 1.82)

1.24 (0.66, 2.31)

Current

12

34

1.01 (0.50, 2.03)

1.17 (0.57, 2.37)

Current Mixed Use

332

1252

0.76 (0.59, 0.99)

0.85 (0.65, 1.11)

Remote use of any drug (Ref)

99

287

1.0

1.0


Disclosure: Y. Lahoud, None; C. Peloquin, None; Y. Zhang, None; D. Misra, None.

To cite this abstract in AMA style:

Lahoud Y, Peloquin C, Zhang Y, Misra D. Effect of Anti-Diabetic Medications on Fracture Risk in Type II Diabetes Mellitus [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/effect-of-anti-diabetic-medications-on-fracture-risk-in-type-ii-diabetes-mellitus/. Accessed May 26, 2022.
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/effect-of-anti-diabetic-medications-on-fracture-risk-in-type-ii-diabetes-mellitus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.